Facilitation by opiate antagonists of sexual performance in the male rat

Behavioral, Neural, and Molecular Mechanisms of Conditioned Mate Preference: The Role of Opioids and First Experiences of Sexual Reward

Although mechanisms of mate preference are thought to be relatively hard-wired, experience with appetitive and consummatory sexual reward has been shown to condition preferences for partner related cues and even objects that predict sexual reward. Here, we reviewed evidence from laboratory species and humans on sexually conditioned place, partner, and ejaculatory preferences in males and females, as well as the neurochemical, molecular, and epigenetic mechanisms putatively responsible. From a comprehensive review of the available data, we concluded that opioid transmission at μ opioid receptors forms the basis of sexual pleasure and reward, which then sensitizes dopamine, oxytocin, and vasopressin systems responsible for attention, arousal, and bonding, leading to cortical activation that creates awareness of attraction and desire. First experiences with sexual reward states follow a pattern of sexual imprinting, during which partner- and/or object-related cues become crystallized by conditioning into idiosyncratic “types” that are found sexually attractive and arousing. These mechanisms tie reward and reproduction together, blending proximate and ultimate causality in the maintenance of variability within a species.

Tramadol's Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats

Tramadol is an effective pharmacological intervention in human premature ejaculation (PE). To investigate whether the inhibitory action of tramadol is primarily caused by its selective serotonin reuptake inhibitory (SSRI) effects we tested the dose–response effects of tramadol on sexual behavior in serotonin transporter wild type (SERT^+/+), heterozygous (SERT^+/-), and knockout (SERT^-/-) rats. To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. Tramadol dose-dependently decreases sexual activity in all genotypes. In all studies, SERT^+/- rats did not respond differently from SERT^+/+ rats. WAY100,635 did not affect sexual activity in SERT^+/+, but dose-dependently reduced sexual activity in SERT^-/- rats. WAY100,635 (0.3 mg/kg) combined with tramadol (20 mg/kg) significantly reduced sexual activity in SERT^+/+ and even stronger in SERT^-/- rats. Naloxone did not affect sexual behavior consistently in SERT^+/+ rats, while in SERT^-/- rats all doses reduced ejaculation frequency mildly. Combining naloxone (20 mg/kg) and tramadol (20 mg/kg) decreased ejaculation frequencies in both genotypes. Interestingly, combining tramadol (20 mg/kg), WAY100,635 (0.3 mg/kg) and naloxone (20 mg/kg) led to complete elimination of all sexual activity in both SERT^+/+ and SERT^-/- rats. These findings suggest that the inhibitory effects of tramadol on male sexual behavior in SERT^+/+ rats is mainly, if not exclusively, due to SERT inhibition, with an important role for 5-HT_1A receptors, although influence of other systems (e.g., noradrenergic) cannot be excluded. As SSRIs exert their sexual inhibition after chronic administration, tramadol may be therapeutically attractive as “on demand” therapy for PE.

Sexual performance and precontact 50-kHz ultrasonic vocalizations in WAG/Rij rats: effects of opioid receptor treatment

WAG/Rij rats are genetically selected animals that model absence epilepsy in rats. Ultrasonic vocalizations and sexual behavior - both ethologically relevant markers of reward system functioning - are poorly described in this strain. The aim of our experiment was to investigate reward-dependent precontact 50-kHz vocalizations (PVs) and copulatory behavior as well as the effects of opioid receptor treatment on such behaviors in sexually experienced WAG/Rij males and rats from two control strains: Sprague-Dawley and Crl: Han Wistar. We analyzed the effects of the opioid receptor antagonist naltrexone (3 mg/kg) and the agonist morphine (1 mg/kg) administration. Additionally, we analyzed the initiation of copulation in sexually naïve males before drug treatment. A significantly lower number of sexually naïve WAG/Rij rats initiated copulation. Sexually experienced WAG/Rij males differed at the control session (after physiological saline treatment) compared with Sprague-Dawley rats: WAG/Rij rats displayed more 50-kHz precontact vocalizations and had longer mount and intromission latencies, longer ejaculation latency, longer postejaculatory latency to exploration, longer 22-kHz vocalization duration after ejaculation, and longer postejaculatory intromission latency. Compared with Crl: Han Wistar rats, WAG/Rij males displayed longer mount latency and shorter 22-kHz vocalization duration. Neither naltrexone nor morphine affected PVs in all groups. On the other hand, opioid receptor treatment differently influenced the number of intromissions required to achieve ejaculation and 22-kHz postejaculatory vocalization duration in WAG/Rij rats than in both control groups. This suggests functional differences in the opioid system in this strain. As a result of the number of males that initiated copulation as well as the number of intromissions to ejaculation and 22-kHz postejaculatory vocalizations which all depend on D1 receptor activation, we suggest that the proportion of opioid receptor to D1 receptors in WAG/Rij rats is different when compared with the control strains. The reward system of Wag/Rij rats with absence epilepsy is sensitive to social rewards (high level of precontact 50-kHz ultrasounds) although this strain displays a lower level of sexual motivation (longer mount latency) compared with other control strains. A lower number of sexually naïve rats initiating copulation and longer mount latency in sexually experienced males could suggest a moderate depressive-like syndrome in this strain of rats.

The effects of opioids and opioid analogs on animal and human endocrine systems

Opioid abuse has increased in the last decade, primarily as a result of increased access to prescription opioids. Physicians are also increasingly administering opioid analgesics for noncancer chronic pain. Thus, knowledge of the long-term consequences of opioid use/abuse has important implications for fully evaluating the clinical usefulness of opioid medications. Many studies have examined the effect of opioids on the endocrine system; however, a systematic review of the endocrine actions of opioids in both humans and animals has, to our knowledge, not been published since 1984. Thus, we reviewed the literature on the effect of opioids on the endocrine system. We included both acute and chronic effects of opioids, with the majority of the studies done on the acute effects although chronic effects are more physiologically relevant. In humans and laboratory animals, opioids generally increase GH and prolactin and decrease LH, testosterone, estradiol, and oxytocin. In humans, opioids increase TSH, whereas in rodents, TSH is decreased. In both rodents and humans, the reports of effects of opioids on arginine vasopressin and ACTH are conflicting. Opioids act preferentially at different receptor sites leading to stimulatory or inhibitory effects on hormone release. Increasing opioid abuse primarily leads to hypogonadism but may also affect the secretion of other pituitary hormones. The potential consequences of hypogonadism include decreased libido and erectile dysfunction in men, oligomenorrhea or amenorrhea in women, and bone loss or infertility in both sexes. Opioids may increase or decrease food intake, depending on the type of opioid and the duration of action. Additionally, opioids may act through the sympathetic nervous system to cause hyperglycemia and impaired insulin secretion. In this review, recent information regarding endocrine disorders among opioid abusers is presented.

Effects of central administration of naloxone during the extinction of appetitive sexual responses

Several studies indicate that opioids are involved in the control of consummatory sexual behavior in male Japanese quail. Naloxone has been reported to increase copulatory responses. In the current study, the effect of naloxone on appetitive sexual behaviors was assessed during extinction test trials. Naloxone was found to substantially reduce appetitive responding, suggesting that opioids differentially affect anticipatory and contact components of sexual behavior.

Naltrexone-induced augmentation of sexual response in men

BACKGROUND

To ascertain the role of endogenous opioids in sexual response, naltrexone, an opiate receptor antagonist, was administered to men, and its effect on selected self-report measures of sexual response to masturbation was recorded.

METHODS

The data are based on results from 20 healthy, sexually active (alone or with a partner) men, aged 20-29 years, who ingested naltrexone (25 mg/day x 3) or placebo in a randomized, double-blind crossover design. There was at least a 14-day interval between drug and placebo treatment. Between 18 and 22 h after the most recent dose of drug or placebo, subjects viewed sexually explicit videos in privacy for 2 h. They were instructed to masturbate and have as many orgasms as desired. The following three different self-report measures of their responses were recorded: number of orgasms; intensity of sexual arousal, and orgasmic intensity.

RESULTS

Under the naltrexone condition, the volunteers experienced a significantly greater mean number of orgasms (3.4 +/- 0.2 SEM) than under the placebo condition (2.6 +/- 0.3). The total number of orgasms was 67 under the naltrexone condition and 51 under the placebo condition. At the first orgasm, the measure of intensity of arousal was significantly greater in the naltrexone (3.9 +/- 0.2) than placebo (3.4 +/- 0.2) condition, and the measure of orgasmic intensity was significantly greater in the naltrexone (3.7 +/- 0.2) than in the placebo (3.0 +/- 0.3) condition.

CONCLUSIONS

The present study provides evidence that endogenous opioids modulate orgasmic response and the perceived intensity of sexual arousal and orgasm in men. The findings suggest that naltrexone could be clinically useful in cases of inhibited sexual desire and erectile dysfunction.

Differential sexual activity of isolated and group-housed male mice: lack of substantial influence of acute or chronic naloxone administration

Influences of naloxone upon male sexual behavior were examined using two different baseline activity levels: individually and group-housed mice. In Experiment 1, single injections of 0,12.5, or 50 micrograms per animal were administered before testing. Isolated mice showed more sexual activity than did grouped mice; naloxone failed to alter those differences. In Experiment 2, a similar result was obtained despite administration of 50 or 150 micrograms per animal of naloxone. In Experiment 3,0 or 50 micrograms of naloxone was administered to isolated or grouped males daily on the 5 days before testing. Isolated mice showed performance superior to that of grouped mice, but there was no effect of the drug. In Experiment 4, doses of 0. 12.5, or 50 micrograms of naloxone were given to isolated or grouped males twice daily for 7 days prior to testing, producing little effect. These results suggest that the influences of prior social condition on male sexual activity are robust in the face of naloxone administration.

Effects of morphiceptin in the medial preoptic area on male sexual behavior

Morphiceptin, a selective mu opioid agonist, injected into the medial preoptic area (MPOA), delayed the onset of copulation in male rats, but did not affect genital reflexes, sexual motivation or general motor activity. In a dose-dependent manner, morphiceptin (100 ng and 1000 ng) injected into the MPOA increased mount and intromission latencies. Similar injections of morphiceptin into the ventromedial hypothalamus had no effect on any parameter of copulation. The increase in copulatory latencies following the injection of the highest dose of morphiceptin was blocked by pretreatment with the opioid antagonist naloxone. In the X-maze task, morphiceptin had no effect on sexual motivation, as measured by the percentage of trials on which the male chose the female's chamber, but it increased the number of trials in which the subject did not select a chamber within 60 s and the latency to the female the first time he chose her chamber. Similar to the copulation task, the mount and intromission latencies were also increased in the X-maze, after the male reached the female. Morphiceptin in the MPOA had no effect on ex copula genital reflexes, tested in restrained supine males, or on motor activity, tested in a grid box. These results suggest that morphiceptin disrupts either the specific copulatory somatomotor pattern or a more general motivational component.

Opioid antagonists and the sexual satiation phenomenon

This study evaluates the effects of the IP injection of naloxone (0.3, 3 and 30 mg/kg) and naltrexone (0.2, 2 and 20 mg/kg) on the sexual satiation phenomenon. It was found that both antagonists exert a dose-based biphasic effect on the proportion of sexually exhausted rats displaying copulation. The intermediate doses of both opioid antagonists were more effective than the low and high doses in increasing the percentage of animals engaged in copulation. The analysis of the specific sexual behaviour parameters revealed that naloxone produces a slight inhibitory effect at the lowest dose, evidenced as an increase in the intromission number. The higher doses of this compound facilitated copulation reflected as a shortening of the ejaculation latency and the interintromission interval (III) and an increase in the copulatory rate. Naltrexone treatment had only facilitatory effects at the lower doses by reducing the III. The higher doses of naloxone (3 and 30 mg/kg) and the intermediate dose of naltrexone (2 mg/kg) decreased the spontaneous ambulatory behaviour of sexually satiated rats without impairing sexual behaviour execution. Data suggest a participation of the endogenous opioid systems in the sexual inhibition resulting from sexual exhaustion.

Effect of morphine and naloxone on LH response and sexual behavior of rams (Ovis aries)

Effects of the opiate agonist, morphine, and antagonist, naloxone, on LH release, courtship behavior and ejaculation frequency of mature, sexually active or sexually inactive rams were investigated. Plasma LH concentrations were monitored from blood samples collected every 15 min for 10 hr (0800 to 1800 hr) from eight rams that were isolated from or in contact with estrous females. Plasma LH concentration was higher (P < .05) in sexually active rams exposed to receptive females compared with hormone concentration of rams isolated from ewes. Intravenous infusion of morphine sulphate (1 mg/kg) into rams 4 and 6 hr after exposure to ewes reduced (P < .05) plasma LH concentration as compared to rams given saline. Morphine did not affect (P > .05) courtship behavior (investigatory sniff, mount attempt, foreleg kick, flehmen, vocalization) but diminished (P < .05) number of ejaculations. In another trial, LH concentrations were higher (P < .05) in seven sexually active rams given naloxone iv or when given to three rams through an intracerebroventricular cannula (icv) as compared to LH response of sexually inactive rams. LH did not differ (P > .05) in seven sexually inactive rams before or after administration of naloxone. Investigatory sniffs by sexually active rams were increased (P < .03) after treatment with the opiate antagonist. Four of the seven sexually active rams had more ejaculations after naloxone compared with the pretreatment period, but mean ejaculation frequency after treatment did not differ (P = .31). Naloxone did not stimulate courtship behavior of sexually inactive males.(ABSTRACT TRUNCATED AT 250 WORDS)

Ejaculation induced changes in escape latency in the hot plate test: pharmacological analysis of anxiolytic versus analgesic effect

The possible changes in nociception at various stages of male sexual behaviour were explored in the hot plate test. Although other authors have reported an antinociceptive effect of mating, we failed to find this effect on the hot plate test after several sexual behaviour events. To further explore the possible antinociceptive action of copulation we administered a suboptimal analgesic dose of morphine (0.3 mg/kg i.p.). No change in nociception were observed in animals treated with a subthreshold dose of morphine and tested in the nociception test after ejaculation were observed. Since previous reports have refered that ejaculation produces hypoalgesia when measured in the hot plate test, we attempted to replicate these findings. We found that one ejaculation produces an increase in the latency to escape in male rats previously habituated to the hot plate test. These results suggest a hypoalgesic effect. However, such changes could also be interpreted as alterations in the animals' emotionality. Thus, a group of habituated animals was tested on the switched off plate. An important increase in the escape latency behaviour after ejaculation was observed, while no differences between control animals, without sexual behaviour display, tested on switched on and switched off plate were observed. The participation of the benzodiazepine and opiod systems in the ejaculation effect on the switched off plate was explored. A similar increase in escape latency to that induced by ejaculation was caused by diazepam (1.0 and 2.0 mg/kg). The increase in escape latency induced by ejaculation was prevented by the benzodiazepine antagonist, flumazenil (20.0 mg/kg).(ABSTRACT TRUNCATED AT 250 WORDS)

Estrogenic regulation of proenkephalin mRNA expression in the ventromedial hypothalamus of the adult male rat

Endogenous opioid peptides and their receptors are regulated by gonadal steroid hormones in the rat hypothalamus. Recent evidence suggests that gonadal steroids are capable of regulating the expression of proenkephalin (PE) mRNA in the ventromedial hypothalamus (VMH) of female, but not male rats. Therefore, we examined the effect of gonadectomy with or without four weeks of hormone treatment on PE mRNA expression in adult male Fisher 344 rats using quantitative in situ hybridization histochemistry. Gonadectomy reduced plasma testosterone and dihydrotestosterone (DHT) levels compared to intact rats, while subsequent estradiol (E2) or DHT treatment increased plasma E2 and DHT levels, respectively. Furthermore, gonadectomy reduced PE mRNA expression in the VMH, but not in the striatum nor the olfactory tubercle compared to intact rats, and this reduction was prevented in the presence of E2, but not DHT. The results suggest that the activation of estrogen receptors normally functions to maintain the level of VMH PE mRNA expression, which is sensitive to hormonal regulation in adult male rats. Thus gonadal steroid hormones might regulate those reproductive functions which are modulated by PE-derived opioid peptides in the male rat brain.

New treatments for erectile impotence

The range of interventions available for the treatment of erectile failure has increased in the past ten years. A significant development is intracavernosal injection of vasoactive drugs, but this treatment is far from ideal. Other, less invasive, pharmacological interventions are being investigated; as yet, none of these appear effective enough to have any significant clinical impact. External vacuum devices are a viable option for some patients, and penile prostheses have become increasingly sophisticated, although research examining their benefits has not. The range of available treatment methods and the growing complexity of the assessment for erectile problems demands an eclecticism of approach which can best be provided by multidisciplinary clinics specialising in sexual dysfunctions.

Sexually dimorphic, androgen sensitive, enkephalinergic afferents to a lumbar motor nucleus of rats

In male rats, methionine-enkephalin immunoreactivity (enkephalin-ir) has been observed in the dorsal lateral nucleus (DLN), a longitudinal pool of motoneurons in the lumbar spinal cord. Within the DLN a mediodorsal crescent of intense enkephalin-ir staining surrounds the motoneurons innervating the ischiocavernosus muscle of the penis, which suggests a function of the enkephalinergic afferents in male copulatory activities. The present study attempted to determine the roles of gender and adult exposure to androgen in shaping the striking subnuclear distribution of enkephalin-ir. Transverse sections through L5-6 were obtained from mature male and female rats that were gonadally intact, gonadectomized, or gonadectomized and treated with testosterone, as well as from male rats genetically deficient in androgen receptors (Tfm). The sections were incubated with primary antiserum raised against methionine enkephalin and bound antibodies were visualized using the avidin-biotin-peroxidase technique. A microphotometer was used to compare the staining density in laminae I-II of the dorsal horn, ventral grey matter, and the DLN. In all groups the DLN stained more darkly than the ventral grey, demonstrating the presence of enkephalin-ir in the DLN regardless of gender or exposure to androgen. However, the mediodorsal crescent of dense staining in the DLN was obvious only in gonadally intact males, while the entire DLN stained darkly in both sexes of gonadectomized rats treated with androgen. Therefore, the preferential distribution of enkephalin-ir in the mediodorsal crescent of the DLN is sexually dimorphic though the overall content of enkephalin-ir within the DLN responds to androgen.

Yohimbine and naloxone: effects on male rat sexual behavior

We evaluated the effects of yohimbine (2 mg/kg) and naloxone (5 mg/kg), separately and in combination, on copulatory behavior in male rats. In Experiment 1, yohimbine evinced decrements in intromission frequency, ejaculation latency, and copulatory efficiency, whereas naloxone administration was followed by an increased ejaculation latency, and the combination of yohimbine plus naloxone was without effect. In Experiment 2, yohimbine evinced decreases in intromission frequency, ejaculation latency, copulatory efficiency in the first, but not subsequent, copulatory series, as well as a decreased latency to sexual exhaustion. Further, treatment with yohimbine alone, naloxone alone, or yohimbine plus naloxone was followed by a reduction in the number of ejaculation prior to sexual exhaustion. Thus, at the doses tested, no synergistic effects were observed for the combination of yohimbine plus naloxone.

Failure of naloxone to block the reduction in burying behaviour after ejaculation in male rats

In the present study we analyzed whether the opiate nociceptive system participates in the reduction in burying behaviour observed after ejaculation. To that purpose the opiate antagonist naloxone (0.5, 1.0 and 2.0 mg/kg) was administered before ejaculation. The results showing that this antagonist does not interfere with the drastic reduction in burying behaviour suggest that an opiate nociceptive mechanism is not involved in this effect. Present data further support the idea that the reduction in burying behaviour is reflecting a specific reduction in anxiety.

Prodynorphin peptide distribution in the forebrain of the Syrian hamster and rat: a comparative study with antisera against dynorphin A, dynorphin B, and the C-terminus of the prodynorphin precursor molecule

The neuroanatomical distribution of the prodynorphin precursor molecule in the forebrain of the male Syrian hamster (Mesocricetus auratus) has been studied with a novel antiserum directed against the C-terminus of the leumorphin [dynorphin B (1-29)] peptide product. C-peptide staining in sections from colchicine-treated hamsters is compared to staining in sections from untreated animals. In addition, the pattern of C-peptide immunostaining in hamster brain is compared to that in the rat brain. Finally, the C-peptide immunolabeling patterns in hamsters and rats are compared to those obtained with antisera to dynorphin A (1-17) and dynorphin B (1-13). Areas of heaviest prodynorphin immunoreactivity in the hamster include the hippocampal formation, lateral septum, bed nucleus of the stria terminalis, medial preoptic area, medial and central amygdaloid nuclei, ventral pallidum, substantia nigra, and numerous hypothalamic nuclei. Although this C-peptide staining pattern is similar to dynorphin staining reported previously in the rat, several species differences are apparent. Whereas moderate dentate gyrus granule cell staining and no CA4 cell staining have been reported in the rat hippocampal formation, intense immunostaining in the dentate gyrus and CA4 cell labeling are observed in the hamster. In addition, the medial preoptic area, bed nucleus of the stria terminalis, and medial nucleus of the amygdala stain lightly for prodynorphin-containing fibers and cells in the rat, compared to heavy cell and fiber staining in the hamster in all three of these regions. In the rat there is no differential staining between tissues processed with the C-peptide, dynorphin A, and dynorphin B antisera, but numerous areas of the hamster brain show striking differences. In most hamster brain areas containing prodynorphin peptides, the C-peptide antiserum immunolabels more cells and fibers than the dynorphin B antiserum, which in turn labels more cells and fibers than dynorphin A antiserum. However, exceptions to this hierarchy of staining intensity are found in the lateral hypothalamus, substantia nigra, arcuate nucleus, and habenula. The differences in staining patterns between rat and hamster are greatest when C-peptide antiserum is used; apparent species differences are present, though less pronounced, in dynorphin B- and dynorphin A-immunostained material.

The colocalization of substance P and prodynorphin immunoreactivity in neurons of the medial preoptic area, bed nucleus of the stria terminalis and medial nucleus of the amygdala of the Syrian hamster

To determine the extent of colocalization of substance P (SP) and prodynorphin peptides within neurons of the medial nucleus of the amygdala (AMe), medial bed nucleus of the stria terminalis (BNSTm) and medial preoptic area (MPOA), we incubated colchicine-treated Syrian hamster brain tissue in an antiserum mixture containing rat anti-SP antibody combined with 1 of 3 rabbit antibodies against prodynorphin peptides: anti-dynorphin A(1-17), anti-dynorphin B(1-13) or anti-C-peptide. This was followed by incubation in a secondary antiserum mixture containing fluorescein-labelled anti-rabbit and rhodamine-labelled anti-rat antibodies. Sections were viewed with an epifluorescence microscope using blue light excitation for fluorescein and green light excitation for rhodamine. Colocalization of SP and prodynorphin labelling was observed in neurons of the caudal parts of AMe, BNSTm and MPOA, areas which are essential for male mating behavior. The colocalization was most extensive in the dorsolateral part of the caudal MPOA, the caudodorsal part of the BNSTm, and in the posterodorsal subdivision of AMe. Although all 3 dynorphin peptides coexisted with SP in these areas, dynorphin B did so less than C-peptide, and dynorphin A less than dynorphin B.

Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites

It is known that the same peptide can be identified in different secretory tissues and in the central nervous system (CNS). We now provide evidence that the same peptides can be found in different organs related to the control of a single function, and speculate on the possibility that this reflects a common neuroendocrine programming. Endogenous opioid peptides (EOP) inhibit the reproductive function acting via the CNS. EOP inhibit gonadotropin secretion in rodents and humans via inhibition of GnRH release and have direct inhibitory actions at the pituitary level via specific binding sites on the gonadotrophs. However, EOP can also be synthesized in the testis and in different compartments of the male genital tract. Several findings indicate that EOP of the reproductive tract have a local, paracrine role. These include: (1) the detection of significant beta-endorphin (beta-EP) production by rat Leydig cells (Lc) in cultures; (2) the hormonal regulation of Lc beta-EP production by positive (gonadotropins) and negative (steroids, glucocorticoids, GnRH) factors; (3) the presence of opioid binding sites (Kd in the nanomolar range) in tubular homogenates and Sertoli cells (Sc) in culture of adult and immature rat testes; (4) the inhibition of basal and FSH-stimulated ABP production by Sc in culture when chronically exposed to beta-EP treatment; (5) the detection of high levels of beta-EP and met-enkephalin in human semen with values 6-12 times higher than in plasma; (6) the evidence for inhibitory functions of seminal opioids on sperm motility, vas deferens muscle contraction and partner immune system. Thus the same peptides, i.e. EOP, may control the reproductive function at multiple sites, operating as a multimessenger system in which the central and peripheral level are unified by the common chemical and inhibitory nature of the message.

Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy

In the present study we evaluated whether naltrexone administration could stimulate sexual function in 30 male patients, ages 25 to 50 years, with idiopathic impotence of at least one year's duration and not of organic etiology. The patients received naltrexone (50 mg/day) or placebo, on a random basis for two weeks. Sexual performance, expressed as the number of full coitus/week, was assessed before (time 0) and during (on days 7 and 15) each treatment. The naltrexone therapy significantly increased the number of successful coitus compared to placebo after 7 and 15 days of treatment: improvement of sexual performance was evident in 11 out of the 15 treated patients. All the patients experienced a significant increase in morning and spontaneous full penile erections/week. No significant side effects were reported. Endocrine studies revealed no significant modification of plasma LH, FSH or testosterone by naltrexone, suggesting that the positive effect of the drug on sexual behavior was exerted at a central level. A two-month follow-up, at which time patients were off treatment, erectile capacity had returned to baseline in 10 patients, while five reported complete recovery of their sexual ability. We hypothesize that an alteration in central opioid tone is present in idiopathic impotence and is involved in the impairment of sexual behavior.

Stimulation of opioid receptors suppresses penile erectile reflexes and seminal emission in rats

The effects of several doses of morphine and naloxone, given alone or in combination, on ex copula tests for rat penile erectile responses and seminal emission were studied. Morphine (0.1, 0.5, 1 and 5 mg/kg IP, 30 min before the test) reduced the proportion of animals showing erections in a dose-related fashion. Seminal emission was apparently more sensitive to opioid inhibition than erectile responses, since it was virtually suppressed by all the doses of morphine tested. Naloxone given alone (0.1, 1 and 10 mg/kg IP, 15 min before testing) was largely ineffective on these genital responses although a significant decrease in the display of erection was observed with the lowest dose. Naloxone (1 mg/kg) efficiently antagonized the effects of morphine (1, 5 and 25 mg/kg) on erectile responses and all but the largest dose of the opiate agonist on seminal emission. These results indicate that, in addition to the well-documented effects of opioids on sexual drive, their effects on the genital reflex potential could play a major role in the sexual deficits associated to opiate intake.

Opioids and sexual behavior in the male rat

Naloxone in the doses of 4 or 16 mg/kg failed to affect copulatory behavior of testosterone-treated castrated male rats. Morphine 10 mg/kg, administered 60 min before behavioral observation, reduced the proportion of animals displaying sexual behavior. Doses of 2.5 or 5 mg/kg reduced the latency to the second ejaculation, whereas the few animals still copulating after morphine 10 mg/kg showed a reduced latency to the first ejaculation. The same doses of morphine administered 5 min before behavioral observation produced a dose-dependent reduction of mount, intromission and ejaculation percentages. However, those animals that did copulate showed a normal copulatory behavior. D-Ala2-Met5 enkephalinamide (DALA) infused into the left cerebral ventricle in a dose of 5 micrograms 5 or 60 min before tests had no effect. When the peptide was infused 30 sec after the first intromission, the number of intromissions as well as the latency to ejaculation were reduced. Opioids may facilitate ejaculatory mechanisms, perhaps as a consequence of their rewarding properties. Moreover, in animals treated with DALA after the first intromission, the number of intromissions and the latency to ejaculation were similar for the first and second copulatory series, while these parameters were much reduced upon the second ejaculation for control animals. It is possible that liberation of endogenous opioids is the cause of ejaculation-induced facilitation of subsequent sexual behavior.

Pharmacological analysis of male rat sexual behavior

Pharmacological influences on male rat sexual behavior are reviewed in an attempt to identify neurotransmitters and their respective receptor types that regulate various factors comprising the behavioral pattern. Evidence is presented that: (1) serotonergic influence is generally inhibitory to sexual behavior, although two receptor subtypes may lower ejaculation threshold; (2) dopaminergic agonists facilitate several aspects of copulatory behavior and ex copula genital responses; (3) noradrenergic activity appears to increase sexual arousal; (4) cholinergic agonists facilitate ejaculation, or in some cases, delay or prevent initiation of copulation; (5) GABA agonists inhibit sexual responses both in and ex copula; (6) opiate agonists appear to inhibit copulation and penile reflexes, although antagonists have mixed effects; (7) ACTH and MSH peptides promote copulatory behavior and genital responses; (8) oxytocin facilitates ex copula penile responses, but may contribute to postejaculatory refractoriness; and (9) long-term exposure to prolactin inhibits sexual behavior and penile responses. Although some progress has been made in identifying neurotransmitter-receptor effects on behavioral components, copulatory behavior is complex and no drug has been found to affect only a single component. Furthermore, drug specificity is only relative.

Opioids and sexual behavior

Opioids have long been known to inhibit sexual behavior. However, it is only within the last decade that the effects of opioids on sexual behavior have been studied extensively and a number of hormonal and neurochemical correlates established. In this review, the experimental literature on opioids and sexual behavior in humans and laboratory animals is examined. Clinical and anecdotal accounts of opioid use are also discussed, in addition to the pharmacology, neuroendocrinology, and biochemistry of opioid administration, to provide a synthesis of critical information. New research directions involving the study of endogenous opioid systems, opioid receptor subtypes, and the opioid modulation of neurotransmitter systems are outlined. Finally, a comprehensive bibliography of the human and animal literature is included.

Alpha-melanocyte-stimulating hormone infusions during pregnancy in the rat: effects on offspring weight, pain reactivity and sexual behavior

Pregnant rats treated during the last third of pregnancy with a continuous infusion of alpha-melanocyte-stimulating hormone (alpha-MSH) produced offspring that weighed less at birth and in adulthood. These offspring of the alpha-MSH treated mothers were less sensitive to pain and as adults showed a reduced analgesic response to morphine. Male offspring of alpha-MSH treated mothers and of control animals responded similarly in sexual performance tests, except that the treated animals significantly shifted their pattern of responding when they encountered a new testing arena or experienced defeat. The offspring of alpha-MSH treated mothers were influenced more by changes in their environment than were control offspring. These effects are similar to those reported following perinatal treatment with opiate drugs or peptides.

Immunohistochemical distribution of substance P, serotonin, and methionine enkephalin in sexually dimorphic nuclei of the rat lumbar spinal cord

The purpose of the present study was to identify chemically some potential inputs to lumbar motoneurons of the rat in the spinal nucleus of the bulbocavernosus, ventral motor pool, dorsolateral nucleus, and retrodorsolateral nucleus. Substance P-like immunoreactivity and serotonin-like immunoreactivity were found in all four motor nuclei, with dense immunoreactive profiles surrounding motoneurons and their processes. Enkephalin-like immunoreactivity was restricted to the sexually dimorphic nuclei, the spinal nucleus of the bulbocavernosus, and the dorsolateral nucleus. Within the spinal nucleus of the bulbocavernosus, enkephalin-like immunoreactive profiles were apposed to the processes of motoneurons but not their somata. In contrast, enkephalin-like immunoreactivity surrounded motoneuron somata in the medial part but not the lateral part of the dorsolateral nucleus, in the location of motoneurons projecting to the ischiocavernosus muscle. Moreover, the density of serotonin-like immunoreactivity was also greater in the medial part of the dorsolateral nucleus. On the basis of the chemo-architecture and the connections of the dorsolateral nucleus, we suggest the division of this motor column into a medial part composed of ischiocavernosus motoneurons surrounded by enkephalin- and serotonin-like immunoreactivity and a lateral part that contains neurons that project to the sphincter urethrae muscle. Total spinal transection severely depleted both serotonin-like and substance P-like material in the lumbar ventral horn. No changes in the distribution of enkephalin-like immunoreactivity were observed following this lesion. It is therefore suggested that in the ventral horn, substance P- and serotonin-like material are derived from supraspinal tracts, whereas enkephalin-like material is derived from intrinsic nerve cell bodies of the spinal cord.

Mating produced analgesia in the Syrian hamster

A series of experiments examined the hypothesis that mating produced analgesia in the Syrian hamster can be blocked by opiate antagonists. The first experiment established a dose response relation to painful footshock. Females were more responsive to footshock than males (p less than 0.001). The second experiment demonstrated that ten minutes of mating reduced responsiveness of both males and females to a moderate intensity of footshock. The third experiment replicated the effect of mating on the responsiveness of males to footshock, but did not demonstrate any effect of the opiate antagonist naltrexone on mating induced analgesia. The fourth experiment demonstrated that limited mating stimulation (five intromissions) has little effect on the responsiveness of sexually inexperienced males to footshock. The fifth experiment replicated the fourth experiment using sexually experienced males and obtained comparable results. Apparently mating induced analgesia in male hamsters is not blocked by opiate antagonists and which raises questions about biological activity of reported changes in endorphin activity during mating.

Opiate antagonists and copulatory behavior of male hamsters

A possible role of endogenous opioids in male copulatory behavior was examined in six experiments which studied the effects of opiate antagonists on the copulatory behavior of male hamsters (Mesocricetus auratus). In Experiment 1, the acute administration of naloxone hydrochloride (4 mg/kg, SC) ten minutes before testing significantly decreased mount frequency, intromission frequency, and ejaculation latency. In Experiment 2 males were tested weekly for three weeks. Half of the males were injected with naloxone ten minutes before each test and half with physiological saline. Naloxone administration reduced mount frequency, and intromission frequency while increasing the postejaculatory interval and the proportion of males displaying behavioral signs of satiety. In Experiment 3 similar effects were obtained following daily administration of naltrexone hydrochloride (10 mg/kg/day SC). In Experiment 4 males were allowed to mate to satiety. Naloxone treated males were more likely to display behavioral signs of satiety during the first ten minutes of these tests. In Experiment 5 it was demonstrated that naloxone administration did not alter the duration of insertion during either intromissions or ejaculations. In Experiment 6 the administration of naloxone did not facilitate the display of copulatory behavior by sexually inactive males. Overall the results are consistent with the hypothesis that opiate antagonists alter male copulatory behavior by enhancing the impact of stimuli occurring during the sexual interaction.

Naltrexone facilitation of sexual receptivity in the rat

Naltrexone hydrochloride (3mg/kg) facilitated sexual receptivity in ovariectomized female rats given estradiol benzoate 44 hr previously. The latency of naltrexone facilitation is 3 hr, which is similar to that by progesterone. Other doses of naltrexone (1 and 5 mg/kg) were ineffective. Unlike the effect of progesterone, the facilitation of behavior by naltrexone is not blocked by the protein synthesis inhibitor anisomycin. Naltrexone facilitation was blocked by pargyline, a monoamine oxidase inhibitor.

Inhibition of mating by naloxone or morphine in recently castrated, but not intact male rats

Administration of naloxone (SC 5 mg/kg) significantly reduced ejaculation and mounting in male rats in the weeks following castration. A similar effect was obtained by injecting morphine (SC 1 or 5 mg/kg). In contrast, the same dosages of naloxone or morphine did not affect the sexual performance of gonadally intact males. Opioid peptides may contribute to the temporary persistence of sexual behavior in testosterone-deficient male mammals, in which incentive qualities of the female partner are an important determinant of sexual arousal.

The sexually dimorphic region of the preoptic area in rats contains denser opiate receptor binding sites in females

Quantitative autoradiographic analysis of opiate receptor binding using [3H]naloxone shows higher levels in the sexually dimorphic region of the medial preoptic area in female rats than in males. Opiate receptor density varies across the estrous cycle being densest in diestrous females. The sexually dimorphic nucleus of the preoptic area lies within the opiate receptor-rich region. Endogenous opiates in the medial preoptic region acting at opiate receptors which are of differential density in males and females could influence sex-specific behavior mediated by the region.

Beta-endorphin suppression of lordosis behavior in female rats; lack of effect of peripherally-administered naloxone

Endogenous opioid peptides have been implicated in the control of copulatory behavior of the male rat. In order to assess the possible role of opioids in modulation of sexual receptivity in the female rat, lordosis behavior of ovariectomized (OVX) steroid-primed rats was tested after administration of beta-endorphin (B-END) or naloxone (NAL). Lordosis-to-mount ratio (L/M) of estrogen (E) - and progesterone (P) -primed rats was suppressed 15 and 45 minutes after intraventricular infusion of 100 ng B-END. This suppressive effect was blocked by subcutaneous injections of NAL (2 mg/kg). NAL alone, however, failed to enhance L/M in E-primed rats when administered in subcutaneous doses of 2 or 40 mg/kg. Thus, B-END is capable of suppressing lordotic responsiveness, but endogenous B-END does not appear to tonically suppress responsiveness in the E-primed rat.

Effects of opiate antagonists on hormones and behavior of male and female rhesus monkeys

Opiate antagonists, naloxone (100 micrograms/kg) and naltrexone (1 mg/kg) were given to singly housed adult male or female rhesus prior to a 20-minute behavioral test with an oppositely sexed stimulus monkey. Four of the intact adult males were socially and sexually experienced. The remaining two intact males and two castrated males had been reared in socially restricted conditions and were psychosexually deficient. Adult females were ovariectomized, and the effects of opiate antagonists were examined with or without concurrent estradiol treatment. Both antagonists inhibited sexual behavior of the socially reared, sexually active, intact males. No stimulatory effects on sexual behavior were observed for sexually deficient males, whether intact or castrated. Females showed little change in sexual behavior following opiate antagonist treatment, regardless of endocrine status. The proportion of approaches of the female to the male was increased when naloxone, but not naltrexone, was given. Specific endocrine effects of the opiate antagonists were only found in intact males. Naltrexone significantly increased LH concentrations in the two males tested, while the increase in LH in the four males receiving naloxone was not significant. In all intact males, increases in LH were accompanied by statistically significant increases in circulating concentrations of testosterone following naloxone and naltrexone. The gonadotropic stimulating effect of the opiate antagonists was specific to LH, and no changes were observed in circulating concentrations of FSH in either sex.

Effects of prenatal exposure to morphine sulfate on reproductive function of female rats

The purpose of this study was to investigate the effect of prenatal exposure to morphine sulfate on the development of reproductive function in female rats. Female rats exposed to morphine sulfate in utero (5-10 mg/kg on days 5-12 of gestation) exhibited varying dates of vaginal opening and a partial inhibition in adult feminine sexual behavior when compared to controls. However, the estrogen binding capacity of hypothalamic cytosols from morphine- and saline-treated females was identical. While we cannot rule out the possibility that the observed changes in reproductive function were an indirect result of morphine-induced alterations in maternal physiology or behavior, these results suggest that the development of feminine sexual behavior can be influenced during the early prenatal period and that morphine sulfate can affect the process of feminization.

beta-Endorphin regulates lordosis in female rats by modulating LH-RH release

Several lines of evidence have implicated the endogenous opioid peptides in the regulation of masculine sexual behaviour. However, although the opioid related peptides alpha-melanocyte stimulating hormone (alpha-MSH) and adrenocorticotropin (ACTH) have been shown to affect lordosis behaviour in the female rat, there is as yet no evidence for a role of the endogenous opiates in the regulation of female sexual behaviour. We present here evidence that the endogenous opiates in the mesencephalic central grey (MCG) are involved in the control of lordosis behaviour in the female rat.

Enkephalins and opiate antagonists control calmodulin distribution in neuroblastoma-glioma cells

The calcium binding protein calmodulin and the opiate receptor binding sites are unevenly distributed in various subcellular fractions of neuroblastoma-glioma NG108-15 cells. The crude mitochondrial-membrane fraction of these cells contains two membrane fractions that are separable by sucrose gradient centrifugation. These two differ in the content of both calmodulin and opiate receptors. Leucine enkephalin and D-Ala2-methionine enkephalinamide decrease the amount of membrane-bound calmodulin in the NC108-15 cells in a time- and dose-dependent manner, whereas the opiate antagonists naloxone and levallorphan have an opposite effect. Naloxone blocks the effect of leucine enkephalin and dextrallorphan has no significant effect. The opiate alkaloids entorphine and phenazocine induce changes similar to that of the enkephalins whereas morphine is inactive even at high concentrations. The alteration in the amount of membrane-bound calmodulin after a short incubation (15 min) with the enkephalins or with naloxone is reflected as an opposite change in the amount of calmodulin in the cell cytosol. Naloxone and levallorphan also increase the number of opiate receptors in NG108-15 cells but dextrallorphan has no such effect. Modulation of the intracellular distribution of calmodulin by opioid peptides and alkaloids may control the activity of various membrane-bound and cytosolic systems that are calmodulin- and/or calcium-dependent.

Opiate effects on social investigatory behavior of male mice

The effects of morphine and naloxone, alone and in combination, on social investigatory behavior and motor activity was examined in CD-1 male mice. Tests were conducted in a Plexiglas apparatus in which a center area was separated from two adjacent stimulus compartments by wire mesh screens. One compartment housed a female conspecific while the other remained empty and served as a control for non-specific investigatory responses. A photocell bisected the center compartment and recorded motor activity. Male mice were placed individually into the center area and the time spent investigating each screen was recorded using contact circuits during the 15-min test. In Experiment 1, males (N = 11) received saline, 0.1, 1.0 and 10.0 mg/kg morphine sulfate IP 20 min prior to testing. The high dose significantly decreased investigation of the female compartment while investigation of the uninhibited chamber and motor activity were not significantly affected. In a second experiment (N = 16), 3, 10 and 30 mg/kg naloxone administered 30 min prior to testing had no significant effect on any of the measures recorded. In a third group of subjects (N = 16), 3 mg/kg naloxone reversed the decrease in female investigation time observed with 10 mg/kg morphine, indicating an opiate mechanism for these results. These data provide further evidence that an animal model can be used to study the disruption of socio-sexual behavior produced by opiates.

Circulating opioids: possible physiological roles in central nervous function

Evidence is reviewed regarding the release of endorphins by such diverse conditions as stress, long distance running, acupuncture, sexual activity, suggestion and ritualistic dancing ceremonies. Additional evidence is cited regarding possible physiological roles of endorphins in antinociception, socialization, euphoria, some mental disorders, drive states and vegetative functions. The concentration of this latter type of evidence is on conditions during which endorphins seem to be exerting effects on a number of different systems together (for example, euphoria is almost always accompanied by analgesia), and the possibility is suggested that the activation of a number of functions together may be due to a global activation of opiate receptors throughout the CNS. A possible basis for this global activation arises from results from this laboratory indicating the presence of a blood-borne opioid hormone, secreted by the pituitary or by an endocrine gland under pituitary control, which is capable of passing from the blood into the CNS. This diffuse endorphinergic system, which is complementary to the well-established endorphinergic neuronal systems in the CNS, thus derives its property of global action on opiate receptors by the diffuse means by which the hormone reaches its target sites, i.e., by passing through the blood brain barrier. Thus, while each specific endorphin-mediated function can be activated by the activation of its respective neural pathway, it is proposed that the hormonal endorphinergic mechanism is activated to produce a global response provoked by conditions to which a more generalized response, including physiological and behavioural changes, is most appropriate.

Opiate antagonists and sexual behavior in female hamsters

Mating or administration of morphine to female hamsters reliably decreases lateral displacement, a sensitive index of female sexual responsitivity. Morphine's effects are antagonized by naloxone. We asked whether endogenous opiates are significantly involved in the mating-induced inhibition of sexual responsitivity by testing whether naloxone or naltrexone attenuated the mating-induced decreases in lateral displacement. Naloxone (4 mg/kg) increased lateral displacement in only one of three tests in females before mating. Naloxone did not attenuate the mating-induced decreases in lateral displacement or lordosis behavior in either ovariectomized, hormonally supplemented or intact females. Large doses of naltrexone produced no reliable effects on sexual behavior during estrus in unmated females, nor did it attenuate the mating-induced decreases in sexual responding, regardless of the time of day of mating. Naloxone often increases the variability of sexual responding. We conclude that naloxone-sensitive mechanisms do not play a critical role in the expression of sexual behavior in female hamsters.

Methadone reduces sexual performances and sexual motivation in the male Syrian golden hamster

The debilitating effect of opiate drugs on sexual function has been known clinically for hundreds of years but has become a topic of experimental investigation only recently. The purpose of the current study was to examine the effects of the opiate drugs methadone and the opiate blocking drug naltrexone on the sexual behavior of male hamsters. Methadone, administered at dosages of 1, 2, 4, 8, and 16 mg/kg, was found to cause a dose related decline in measures of both sexual performance and sexual motivation, with measures of sexual performance being the more sensitive to the drug. The debilitating effect of methadone was judged to be highly selective for sexual behavior since, for example, at 16 mg/kg of methadone, sexual behavior was eliminated but ambulatory activity was unaffected. Pretreatment with naltrexone blocked the effects of methadone and posttreatment reversed the effects, thereby indicating that the methadone was inhibiting sexual behavior by acting on specific opiate receptors. The results demonstrate that the male hamster is an excellent small animal model for use in studying the mechanisms of opiate induced sexual dysfunction and further support the hypothesis that the endogenous opiates may be involved in the regulation of sexual behavior.

Sexual behavior decreases pain sensitivity and stimulated endogenous opioids in male rats

In male rats copulation has antinociceptive effects as measured either by shock-induced vocalizations or hindlimb withdrawal to pinch. Prolonged mating reduces the content of endogenous opioids in midbrain but not in hypothalamus or caudate nucleus. Blockage of opiate receptors with the narcotic antagonist naloxone (4 mg/kg) significantly extends the postejaculatory interval. The results indicate that mating is a biological stimulus for the release of endogenous opoids, possibly to (a) prevent intense sexual stimulation from becoming aversive, and (b) increase its reward value.

Copulatory behavior and sexual reflexes of male rats treated with naloxone

Two experiments explored a potential role for endogenous opiates in the regulation of sexual behavior of male rats. Specifically, we questioned whether such opiates regulated the refractory period following ejaculation during copulation, or the latency period for the evocation of penile reflexes (erections, cups, and flips) from supine males. Animals were injected IP with 15-45 mg/kg naloxone hydrochloride 30 min prior to the start of reflex testing, and with 7.5-45 mg/kg naloxone hydrochloride 30 min before testing for copulation. Naloxone resulted in a small but reliable decrease in the number of penile flips. Reflex latency and other measures of penile reflexes were unaffected. At all doses used, naloxone significantly prolonged the postejaculatory refractory period, and there were no other effects on copulation.

Threshold differences for naloxone and naltrexone in the hypothalamus and midbrain using fixed ratio brain self-stimulation in rats

Rats were implanted with stimulating electrodes aimed either at the medial forebrain bundle-lateral hypothalamus (MFB-LH) or the midbrain-central gray (MID-GG), and were trained to lever-press for brain self-stimulation on a fixed ratio: 15 schedule of reinforcement. The dose-dependent effects of morphine (0.1-3.0 mg/kg), naloxone (0.1-30 mg/kg), and naltrexone (0.1-30 mg/kg) were then determined during 1 h test sessions. Both naloxone and naltrexone decreased the rate of responding in the MFB-LH as well as in the MID-CG. However, decrements in response rates were produced in the MID-CG by both naloxone and naltrexone at one tenth the doses required to produce similar decrements with electrodes in the MFB-LH. Dose-dependent decreases in response rates produced morphine occurred at the same doses in the two electrode sites. At both sites, the decreases in response rates produced by the highest dose of morphine were antagonized completely by a low dose of naloxone (0.1 mg/kg). At an intermediate dose of naloxone (1.0 mg/kg), antagonism occurred in the MFB-LH but not in the MID-CG. At a high dose of naloxone (10 mg/kg), a depression in lever-pressing occurred at both sites in the morphine-treated animal indicating that the depressive action predominated over antagonism. These data explain the lack of consistency of the effects of naloxone on brain self-stimulation previously reported by different laboratories, and demonstrate that the use of partial reinforcement schedules in a rational approach to the evaluation of opioid effects on brain self-stimulation behavior.

Behavioural and endocrine effects of naltrexone in male talapoin monkeys

The effect of treating captive male talapoin monkeys with naltrexone hydrochloride (500 micrograms/kg intra-muscular injection twice daily) was studied both in socially living and singly caged animals. The behaviour of the group males and endocrine changes in all treated animals were monitored during the course of treatment and on drug withdrawal. Naltrexone significantly reduced sexual behaviour in previously active males, while increasing grooming interactions. Aggressive behaviour did not change. There was an overall significant elevation in testosterone, LH and cortisol during drug treatment and a significant decrease on withdrawal. Changes in prolactin in response to naltrexone depended upon the pre-treatment level of this hormone: in males in which levels were low, there was a significant elevation in prolactin, while in those with high pre-treatment prolactin, levels were unchanged by the drug. The behavioural changes reported for this primate are in direct contrast to changes reported in rodents, while the hormonal changes, except for prolactin, are comparable to others reported.